Overview Dividends

(XYL) Xylem - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US98419M1009

Pumps, Meters, Controls, Filtration, Analytics

XYL EPS (Earnings per Share)

EPS Growth (3Y CAGR): 15.58%
EPS Trend (3Y Correlation): 83.4%

XYL Revenue

Revenue Growth (3Y CAGR): 16.05%
Revenue Trend (3Y Correlation): 83.5%

Risk via 10d forecast
Volatility	20.0%
Value at Risk 5%th	30.5%

Reward
Sharpe Ratio	0.76
Alpha Jensen	4.50

Character
Hurst Exponent	0.562
Beta	1.168

Drawdowns 3y
Max DD	28.73%
Mean DD	8.72%

Description: XYL Xylem September 29, 2025

Xylem Inc. (NYSE: XYL) designs, manufactures, and services engineered water-related products for utility, industrial, residential, and commercial markets worldwide. The firm operates through four segments: Water Infrastructure; Applied Water; Measurement & Control Solutions; and Water Solutions & Services, leveraging brands such as Flygt, Ionpure, Wallace & Tiernan, Rule, Bell & Gossett, Sensus, and Xylem Vue.

In FY 2023 the company generated approximately $5.6 billion in revenue, a 10 % year-over-year increase, with an adjusted EBITDA margin of roughly 22 %. Recurring revenue from smart-metering and data-analytics services now represents about 15 % of total sales, underscoring the shift toward subscription-based, high-margin offerings.

Key macro drivers include rising global water-infrastructure spending (estimated CAGR ≈ 5 % through 2028), stricter ESG regulations that push utilities toward energy-efficient pumps and digital monitoring, and climate-related resilience investments that boost demand for flood-control and wastewater-treatment solutions. Xylem’s exposure to both capital-intensive infrastructure projects and recurring SaaS-type services gives it a diversified revenue profile.

For a deeper quantitative assessment of XYL’s valuation metrics and scenario analysis, you may find the ValueRay platform useful.

XYL Stock Overview

Market Cap in USD	36,839m
Sub-Industry	Industrial Machinery & Supplies & Components
IPO / Inception	2011-10-13
Return 12m vs S&P 500	5.33%
Analyst Rating	4.05 of 5

XYL Dividends

Dividend Yield	1.03%
Yield on Cost 5y	1.79%
Yield CAGR 5y	8.48%
Payout Consistency	100.0%
Payout Ratio	32.2%

XYL Growth Ratios

CAGR	11.56%
CAGR/Max DD Calmar Ratio	0.40
CAGR/Mean DD Pain Ratio	1.33
Current Volume	789.5k
Average Volume	1020.8k

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (948.0m TTM) > 0 and > 6% of Revenue (6% = 533.6m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA 0.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 24.42% (prev 23.28%; Δ 1.14pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.07 (>3.0%) and CFO 1.27b > Net Income 948.0m (YES >=105%, WARN >=100%)

Net Debt (898.0m) to EBITDA (1.79b) ratio: 0.50 <= 3.0 (WARN <= 3.5)

Current Ratio 1.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (244.1m) change vs 12m ago 0.14% (target <= -2.0% for YES)

Gross Margin 38.23% (prev 36.97%; Δ 1.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 53.35% (prev 52.50%; Δ 0.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 38.12 (EBITDA TTM 1.79b / Interest Expense TTM 32.0m) >= 6 (WARN >= 3)

Altman Z'' 2.55

(A) 0.13 = (Total Current Assets 4.44b - Total Current Liabilities 2.27b) / Total Assets 17.30b

(B) 0.20 = Retained Earnings (Balance) 3.47b / Total Assets 17.30b

(D) 0.55 = Book Value of Equity 3.24b / Total Liabilities 5.85b

Total Rating: 2.55 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 68.08

1. Piotroski 6.50pt = 1.50

2. FCF Yield 2.45% = 1.23

3. FCF Margin 10.40% = 2.60

4. Debt/Equity 0.19 = 2.48

5. Debt/Ebitda 0.50 = 2.31

6. ROIC - WACC (= -2.56)% = -3.19

7. RoE 8.67% = 0.72

8. Rev. Trend 83.55% = 6.27

9. EPS Trend 83.40% = 4.17

What is the price of XYL shares?

As of November 13, 2025, the stock is trading at USD 149.78 with a total of 789,500 shares traded.
Over the past week, the price has changed by +0.06%, over one month by +2.59%, over three months by +5.13% and over the past year by +21.61%.

Is Xylem a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Xylem (NYSE:XYL) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 68.08 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XYL is around 148.37 USD . This means that XYL is currently overvalued and has a potential downside of -0.94%.

Is XYL a buy, sell or hold?

Xylem has received a consensus analysts rating of 4.05. Therefore, it is recommended to buy XYL.

Strong Buy: 9
Buy: 5
Hold: 8
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the XYL price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	163.7	9.3%
Analysts Target Price	163.7	9.3%
ValueRay Target Price	167.3	11.7%

XYL Fundamental Data Overview November 10, 2025

Market Cap USD = 36.84b (36.84b USD * 1.0 USD.USD)
P/E Trailing = 39.0982
P/E Forward = 27.7778
P/S = 4.142
P/B = 3.2753
P/EG = 2.4602
Beta = 1.168
Revenue TTM = 8.89b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.79b USD
Long Term Debt = 1.98b USD (from longTermDebt, last fiscal year)
Short Term Debt = 176.0m USD (from shortTermDebt, last quarter)
Debt = 2.09b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 898.0m USD (from netDebt column, last quarter)
Enterprise Value = 37.74b USD (36.84b + Debt 2.09b - CCE 1.19b)
Interest Coverage Ratio = 38.12 (Ebit TTM 1.22b / Interest Expense TTM 32.0m)
FCF Yield = 2.45% (FCF TTM 925.0m / Enterprise Value 37.74b)
FCF Margin = 10.40% (FCF TTM 925.0m / Revenue TTM 8.89b)
Net Margin = 10.66% (Net Income TTM 948.0m / Revenue TTM 8.89b)
Gross Margin = 38.23% ((Revenue TTM 8.89b - Cost of Revenue TTM 5.49b) / Revenue TTM)
Gross Margin QoQ = 38.93% (prev 38.77%)
Tobins Q-Ratio = 2.18 (Enterprise Value 37.74b / Total Assets 17.30b)
Interest Expense / Debt = 0.29% (Interest Expense 6.00m / Debt 2.09b)
Taxrate = 23.91% (71.0m / 297.0m)
NOPAT = 928.4m (EBIT 1.22b * (1 - 23.91%))
Current Ratio = 1.96 (Total Current Assets 4.44b / Total Current Liabilities 2.27b)
Debt / Equity = 0.19 (Debt 2.09b / totalStockholderEquity, last quarter 11.21b)
Debt / EBITDA = 0.50 (Net Debt 898.0m / EBITDA 1.79b)
Debt / FCF = 0.97 (Net Debt 898.0m / FCF TTM 925.0m)
Total Stockholder Equity = 10.93b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 948.0m / Total Assets 17.30b)
RoE = 8.67% (Net Income TTM 948.0m / Total Stockholder Equity 10.93b)
RoCE = 9.45% (EBIT 1.22b / Capital Employed (Equity 10.93b + L.T.Debt 1.98b))
RoIC = 7.22% (NOPAT 928.4m / Invested Capital 12.85b)
WACC = 9.78% (E(36.84b)/V(38.93b) * Re(10.32%) + D(2.09b)/V(38.93b) * Rd(0.29%) * (1-Tc(0.24)))
Discount Rate = 10.32% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.54%
[DCF Debug] Terminal Value 74.40% ; FCFE base≈886.2m ; Y1≈1.09b ; Y5≈1.87b
Fair Price DCF = 88.67 (DCF Value 21.59b / Shares Outstanding 243.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 83.40 | EPS CAGR: 15.58% | SUE: 3.80 | # QB: 4
Revenue Correlation: 83.55 | Revenue CAGR: 16.05% | SUE: 0.87 | # QB: 2

Additional Sources for XYL Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle